Warren Buffett's Successor, Greg Abel, Cashed Out on UnitedHealth. But Is the Stock a Steal at Its Current Valuation?

Source Motley_fool

Key Points

  • UnitedHealth faced challenges last year but has since taken important steps along the recovery and growth path.

  • The company’s strategies are bearing fruit, as we’ve seen in recent earnings reports.

  • 10 stocks we like better than UnitedHealth Group ›

Warren Buffett last year prepared to vacate his spot in the driver's seat at Berkshire Hathaway and hand over the steering wheel to Greg Abel. But before he did so, he bought a few new stocks -- and one of them was UnitedHealth Group (NYSE: UNH), a down-but-not-out health insurance leader. As CEO of Berkshire Hathaway, Buffett added the stock to his portfolio in the second quarter of the year.

At the time, UnitedHealth was struggling with a number of challenges, but Buffett likely viewed it as a strong recovery story, particularly considering the company's market leadership: UnitedHealth is the country's biggest health insurer.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

Earlier this year, though, Abel, in his first quarter as Berkshire Hathaway CEO, decided to cash out on this healthcare giant. He sold the entire position, or 5,039,564 shares. UnitedHealth previously represented 0.6% of Berkshire Hathaway's portfolio.

Now you may be wondering whether this stock, among one of Buffett's last stock picks as CEO, has reached its potential -- or if the stock is a steal at its current valuation. Let's find out.

Two doctors share information in a hospital hallway.

Image source: Getty Images.

Buffett buys, Abel sells

First, let's consider why Buffett may have bought and why Abel may have sold. We don't know the exact reasons, as these investors only declare their trades publicly but aren't required to offer further details. Considering Buffett's investing focus on buying quality companies at reasonable or even bargain prices, we might deduce that he applied this idea when picking up the shares.

Buffett bought UnitedHealth in the second quarter, a time when valuation dropped sharply.

UNH PE Ratio (Forward) Chart

UNH PE Ratio (Forward) data by YCharts

The billionaire probably liked this price tag, along with UnitedHealth's strong moat or competitive advantage. The company dominates the U.S. health insurance market and has two enormous pillars -- the UnitedHealthcare insurance unit and the Optum healthcare services business. It would be very difficult for a rival to copy this model and unseat the market leader.

Meanwhile, UnitedHealth was making clear moves to spur recovery. The company, which struggled with increased patient use of healthcare and higher healthcare costs, cut certain plans and adjusted pricing, for example. UnitedHealth also invested in artificial intelligence (AI) to streamline certain processes and gain efficiency. And all of this has been progressively bearing fruit, as we've seen in recent earnings reports.

UNH Revenue (Quarterly) Chart

UNH Revenue (Quarterly) data by YCharts

Potential reasons for Abel's move

But at the start of this year, Abel decided to part ways with UnitedHealth. Again, we don't know the reasons behind his move. It may have simply been to free up more cash for other stocks that Abel aimed to include in the portfolio. Depending on the exact timing of Buffett's buy and Abel's sell, UnitedHealth could have delivered a gain of more than 20% to Berkshire Hathaway. (This is just an example of what might have happened -- we don't know the exact dates of the buys and sells, so we can't be sure of the return.)

UNH Chart

UNH data by YCharts

In any case, the move doesn't necessarily mean Abel doesn't like the stock or that it isn't right for your portfolio. It's important to keep in mind that professional investors often make moves to support a broader strategy -- so a "sell" doesn't always suggest the fund manager no longer believes in the stock's potential.

With this in mind, has UnitedHealth reached its maximum today? Or is the stock a steal?

At 23x forward earnings estimates, the stock is more expensive than when Buffett added it to the portfolio.

But, it's still cheaper than it was in the past -- and right now we might consider that revenue growth prospects are improving. This is considering the recent aggressive moves UnitedHealth has made to recover and favor growth moving forward.

All of this means that UnitedHealth may not be an absolute steal, but it remains reasonably priced. And that makes it a great healthcare stock to buy today and hold onto for the long term as this recovery story continues to unfold.

Should you buy stock in UnitedHealth Group right now?

Before you buy stock in UnitedHealth Group, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $395,679!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,805!*

Now, it’s worth noting Stock Advisor’s total average return is 929% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of July 13, 2026.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Will the Tech Rally Continue? The Technical Verdict on the NASDAQ 100 Riding a massive 32% post-earnings wave, the Nasdaq-100 is showing its first signs of exhaustion. We break down crucial exit and entry rules for long positions this week.
Author  Mitrade Team
Jun 05, Fri
Riding a massive 32% post-earnings wave, the Nasdaq-100 is showing its first signs of exhaustion. We break down crucial exit and entry rules for long positions this week.
placeholder
Lincoln National vs. MetLife: Which Financial Stock Is a Better Buy in 2026?Key PointsLincoln National offers a specialized focus on U.S. retirement and life insurance markets.MetLife provides massive global diversification across forty international marke
Author  Mitrade Team
Jun 10, Wed
Key PointsLincoln National offers a specialized focus on U.S. retirement and life insurance markets.MetLife provides massive global diversification across forty international marke
placeholder
XRP Price Prediction for July 2026: Can Buyers Finally Break the Downtrend?XRP (XRP) price trades near $1.05, caught between a year-long downtrend and a sudden burst of buying.July has historically rewarded XRP holders. This year the month arrives with on-chain accumulation
Author  Beincrypto
Jun 30, Tue
XRP (XRP) price trades near $1.05, caught between a year-long downtrend and a sudden burst of buying.July has historically rewarded XRP holders. This year the month arrives with on-chain accumulation
placeholder
Today’s Market Recap: Chip Stocks Retreat Collectively, Meta Rises Against the Trend, Non-Farm Payrolls Become the Next Key CatalystOn July 1, Eastern Time, U.S. stocks closed fluctuating lower on the first trading day of the second half of the year. Although some megacap tech stocks such as Meta (
Author  TradingKey
Jul 02, Thu
On July 1, Eastern Time, U.S. stocks closed fluctuating lower on the first trading day of the second half of the year. Although some megacap tech stocks such as Meta (
placeholder
XAUUSD Gold Analysis: Gold Holds Above $4,350 Ahead of US Inflation Data Is $4,500 Next? Gold holds above $4,350 following weak US jobs data. As inflation reports approach and UBS eyes $5,000, can XAUUSD break resistance at $4,435 to rally toward $4,500?
Author  Naoufal Seddik
2 hours ago
Gold holds above $4,350 following weak US jobs data. As inflation reports approach and UBS eyes $5,000, can XAUUSD break resistance at $4,435 to rally toward $4,500?
goTop
quote